Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
180 Life Sciences Corp (ATNF) is a clinical-stage biotechnology company pioneering treatments for inflammatory diseases, fibrosis, and pain through advanced therapeutic platforms. This page serves as the definitive source for official news and developments across the company’s scientific research and blockchain-enabled iGaming initiatives.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, financial announcements, and strategic partnerships. Key focus areas include the company’s anti-TNF fibrosis research, synthetic cannabidiol analogs development, and expansion into blockchain-based gaming technology solutions.
All content is curated to provide accurate, compliance-focused information without speculative commentary. Regular updates ensure stakeholders maintain current awareness of ATNF’s progress in both biotechnology and digital innovation sectors.
Bookmark this page for direct access to press releases, earnings reports, and operational updates from 180 Life Sciences Corp. Check back frequently for the latest developments shaping this innovative dual-sector enterprise.
180 Life Sciences Corp. (NASDAQ: ATNF) announced its participation in the Biotech Showcase 2022 Virtual Conference from January 10-12, 2022. Dr. James Woody, the Company's CEO, will present an overview of its business and is available for virtual meetings. The conference focuses on innovations in the life sciences industry, covering recent opportunities and challenges. 180 Life Sciences is dedicated to developing novel drugs for inflammatory diseases, fibrosis, and pain, leveraging expertise from notable institutions like Oxford and Stanford.
180 Life Sciences (NASDAQ: ATNF) has announced a global licensing agreement with The University of Oxford for the development of HMGB1, a regenerative molecule aimed at promoting liver repair. The agreement involves a small upfront fee with additional payments contingent on clinical milestones. This initiative targets liver disorders such as NASH, a condition with no approved therapies. The collaboration aims to advance GMP production and safety testing in preparation for an Investigational New Drug application.
180 Life Sciences Corp. (NASDAQ: ATNF) announced positive top-line results from its Phase 2b clinical trial for Dupuytren’s disease, demonstrating significant reductions in nodule hardness and size. The trial met both primary and secondary endpoints, showing high patient compliance without serious adverse events. Although detailed data cannot be released due to publication policies, the Company anticipates commercialization discussions with regulatory bodies in 2022. 180 Life Sciences aims to lead in fibrosis therapies, with no current competitors for early-stage Dupuytren’s disease treatments.
180 Life Sciences Corp. (NASDAQ: ATNF) announced a keynote by Professor Jagdeep Nanchahal at the 2021 International Dupuytren Symposium on December 1, 2021. The presentation focused on re-purposing anti-TNF for Dupuytren’s disease and disclosed promising phase 2b clinical trial results. The trial met primary and secondary endpoints, showing significant improvement in nodule hardness and size, with no severe adverse events reported. The full results are pending publication in a peer-reviewed journal, indicating a potential new therapeutic approach for Dupuytren’s disease.
180 Life Sciences Corp. (ATNF) announced the extension of its patent portfolio with new patents granted in the US and Canada for methods treating chronic pain using specific phenyl substituted cyclohexenyl compounds related to cannabidiol (CBD). These patents complement existing protections in Europe, China, and Israel. The company is focusing on synthetic cannabidiol analogues aimed at improving pain management for patients with rheumatoid arthritis. CEO Dr. James Woody noted the potential of these compounds to address unrelieved pain in patients not responding to current therapies.
180 Life Sciences Corp. (NASDAQ: ATNF) announced that Professor Jagdeep Nanchahal will present a keynote on ‘Re-purposing anti-TNF for Dupuytren’s Disease’ at the 2021 International Dupuytren Symposium on December 1, 2021. He will discuss the molecular mechanisms of Dupuytren’s disease and share data from phase 2a and 2b clinical trials. Additionally, the company anticipates starting a frozen shoulder clinical trial in early 2022. 180 Life Sciences is focusing on innovative drug development for unmet needs in inflammatory diseases and fibrosis.
180 Life Sciences Corp. (NASDAQ: ATNF) has appointed Quan A. Vu as Chief Operating Officer/Chief Business Officer. With 20 years in biopharma, Vu has a strong track record in corporate development and negotiations, previously working with companies like Aegis Therapeutics and Sanofi. CEO Dr. James Woody expressed confidence in Vu's ability to enhance the company's drug development efforts. 180 Life Sciences focuses on innovative therapies for inflammatory diseases, leveraging expertise from renowned universities.
180 Life Sciences Corp. (NASDAQ: ATNF) announced the publication of a pre-clinical study on CBG (cannabigerol) derivatives, demonstrating their potential to treat pain, inflammation, and obesity. Conducted in collaboration with experts from Hebrew University and Oxford University, the study highlighted HUM-234's ability to prevent weight gain and improve liver health in high-fat diet mice. The findings support the therapeutic promise of CBG derivatives, with implications for addressing metabolic disorders. The report strengthens the company's position in developing non-psychoactive drugs targeting inflammation and related conditions.
180 Life Sciences (NASDAQ: ATNF) announced it received a Notice of Allowance for its patent application 16/661,769 regarding a method to reduce Post-Operative Cognitive Dysfunction (POCD). This patent comes as a result of innovative research highlighting that administration of anti-TNF antibodies before surgery may lower the risk of delirium in elderly patients post-hip surgery. There are currently no approved treatments for POCD. The company is collaborating with the University of Oxford on a randomized controlled trial to validate these findings and improve patient outcomes.
180 Life Sciences Corp. (NASDAQ: ATNF) announced a Memorandum of Understanding with Celltrion Healthcare for the supply of anti-TNF biosimilar drugs. This collaboration aims to develop anti-TNF therapies for new indications, specifically targeting unmet medical needs in early-stage Dupuytren’s disease, frozen shoulder, and post-operative cognitive deficit. CEO Dr. James Woody expressed optimism about the partnership, anticipating a binding Letter of Intent soon. 180 Life Sciences is also progressing with clinical trials for its candidates, aiming to address significant health challenges.
